Cantex Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing proprietary compounds that enhance the efficacy and safety of the treatment of cancer and blood disorders.

Our lead product candidate, CX-01, is a multi-targeted new chemical entity (NCE). In 2016, we plan to advance CX-01 in a multiple arm randomized Phase IIb clinical trial in newly diagnosed patients with both primary and secondary acute myeloid leukemia (AML) and initiate additional clinical trials in myelodysplastic syndrome (MDS), acute graft versus host disease (GVHD) associated with allogeneic hematopoietic stem cell transplantation (HSCT), and non-small cell lung cancer (NSCLC).

Latest News

Spotlight

Cantex is advancing its lead product candidate, CX-01, into a multiple arm, randomized Phase IIb clinical trial in newly diagnosed patients with both primary and secondary AML and intends to initiate additional clinical trials in MDS, acute GVHD associated with allogeneic hematopoietic stem cell transplantation, and NSCLC.